Publication

Lymph node stromal CCL2 limits antibody responses

Journal Paper/Review - Mar 20, 2020

Units
Keywords
PubMed
Doi
Link
Contact

Citation
Dasoveanu D, Park H, Ly C, Shipman W, Chyou S, Kumar V, Tarlinton D, Ludewig B, Mehrara B, Lu T. Lymph node stromal CCL2 limits antibody responses. Sci Immunol 2020; 5
Project
Type
Journal Paper/Review (English)
Journal
Sci Immunol 2020; 5
Publication Date
Mar 20, 2020
Issn Print
Issn Electronic
2470-9468
Pages
Publisher
Brief description/objective

Nonhematopoietic stromal cells in lymph nodes such as fibroblastic reticular cells (FRCs) can support the survival of plasmablasts and plasma cells [together, antibody-forming cells (AFCs)]. However, a regulatory function for the stromal compartment in AFC accumulation has not been appreciated. Here, we show that chemokine ligand 2 (CCL2)-expressing stromal cells limit AFC survival. FRCs express high levels of CCL2 in vessel-rich areas of the T cell zone and the medulla, where AFCs are located. FRC CCL2 is up-regulated during AFC accumulation, and we use lymph node transplantation to show that CCL2 deficiency in BP3 FRCs and lymphatic endothelial cells increases AFC survival without affecting B or germinal center cell numbers. Monocytes are key expressers of the CCL2 receptor CCR2, as monocyte depletion and transfer late in AFC responses increases and decreases AFC accumulation, respectively. Monocytes express reactive oxygen species (ROS) in an NADPH oxidase 2 (NOX2)-dependent manner, and NOX2-deficient monocytes fail to reduce AFC numbers. Stromal CCL2 modulates both monocyte accumulation and ROS production, and is regulated, in part, by manipulations that modulate vascular permeability. Together, our results reveal that the lymph node stromal compartment, by influencing monocyte accumulation and functional phenotype, has a regulatory role in AFC survival. Our results further suggest a role for inflammation-induced vascular activity in tuning the lymph node microenvironment. The understanding of stromal-mediated AFC regulation in vessel-rich environments could potentially be harnessed to control antibody-mediated autoimmunity.